Umirolimus

Base Information

Chemical Name:Umirolimus
CAS No.:851536-75-9
Molecular Formula:C₅₅H₈₇NO₁₄
Molecular Weight:986.294
Hs Code.:
UNII:U36PGF65JH
Wikipedia:Umirolimus
Wikidata:Q7881588
NCI Thesaurus Code:C152800
RXCUI:1942479
Metabolomics Workbench ID:155527
ChEMBL ID:CHEMBL2107380
Mol file:851536-75-9.mol

Synonyms:40-O-(2-ethoxyethyl)rapamycin;42-O-(2-ethoxyethyl) rapamycin;Biolimus A9;rapamycin, 42-O-(2-ethoxyethyl)-;TRM-986;umirolimus

Suppliers and Price of Umirolimus

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

TRC
Umirolimus
5mg
$ 370.00

TRC
Umirolimus
1mg
$ 85.00

Cayman Chemical
Umirolimus ≥95%
5mg
$ 411.00

Cayman Chemical
Umirolimus ≥95%
1mg
$ 103.00

American Custom Chemicals Corporation
UMIROLIMUS 95.00%
5MG
$ 504.00

AK Scientific
Umirolimus
5mg
$ 613.00

Total 12 raw suppliers

Chemical Property of Umirolimus

Chemical Property:

Boiling Point:991.0±75.0 °C(Predicted)
PKA:10.40±0.70(Predicted)
PSA：193.66000
Density:1.15±0.1 g/cm3(Predicted)
LogP:7.17930
XLogP3:6.8
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:14
Rotatable Bond Count:11
Exact Mass:985.61265645
Heavy Atom Count:70
Complexity:1840

Purity/Quality:

97% ^*data from raw suppliers

Umirolimus ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Canonical SMILES:CCOCCOC1CCC(CC1OC)CC(C)C2CC(=O)C(C=C(C(C(C(=O)C(CC(C=CC=CC=C(C(CC3CCC(C(O3)(C(=O)C(=O)N4CCCCC4C(=O)O2)O)C)OC)C)C)C)OC)O)C)C
Isomeric SMILES:CCOCCO[C@@H]1CC[C@H](C[C@H]1OC)C[C@@H](C)[C@@H]2CC(=O)[C@@H](/C=C(/[C@H]([C@H](C(=O)[C@@H](C[C@@H](/C=C/C=C/C=C(/[C@H](C[C@@H]3CC[C@H]([C@@](O3)(C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)O)C)OC)\C)C)C)OC)O)\C)C
Description Coronary stents have dramatically improved the success rate of interventional cardiology in recent years, and stent implantation has become the standard of care in percutaneous coronary interventions. However, the long-term success of coronary stenting is hampered by a high rate of restenosis (i.e., recurrence of stenosis, or reblocking), which is caused by proliferation and migration of smooth muscle cells and production of extracellular matrix. The Biomatrix DES is a novel stent system combining a biodegradable PLA and the new anti-restenoic drug biolimus. Biolimus is a semi-synthetic analog of sirolimus wherein the hydroxyl moiety at position 42 is modified to an ethoxyethyl ether group. As with rapamycin, the mechanism of action of biolimus consists of forming a complex with intracellular 12-kDa FK506-binding protein (FKBP-12), which binds to the mammalian target of rapamycin (mTOR) and reversibly inhibits cell-cycle transition of proliferating smooth muscle cells.The antiproliferative potency of biolimus is similar to that of sirolimus; however, it is approximately 10-fold more lipophilic than sirolimus, which results in rapid absorption of the drug into fatty tissues and reduced systemic exposure. The Biomatrixs DES is produced by the absorption of a 1:1 combination of biolimus and PLA on a flexible stainless steel stent. The precision automated coating method used in the production of the stent ensures the PLA biolimus combination is applied solely to the abluminal surface of the stent. PLA is co-released with biolimus over 6 9 months, and biodegraded initially to lactic acid, and eventually to carbon dioxide and water.
Uses Umirolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the 42-hydroxy group, providing one of most hydrophobic tacrolimus analogues. Umirolimus has been targeted for use in stents and medical devices to suppress localised immunoreaction. Like all tacrolimus analogues, umirolimus binds to receptor protein, FKBP12. The complex then binds to mTOR and prevents it from interacting with target proteins. Umirolimus is extensively cited in the literature with over 70 citations. Umirolimus is one of two promising agents for the treatment of peripheral artery disease (PAD) and minimize restenosis. Umirolimus is a medical device to suppress localised immunoreaction.

Technology Process of Umirolimus

There total 4 articles about Umirolimus which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 46.0%